Atlas Trials

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Clinical trial NCT03706287 · UNKNOWN

Trial details

NCT number
NCT03706287
Sponsor
Sichuan Cancer Hospital and Research Institute
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lung Cancer Metastatic
Start date
2018-12-06
Primary completion
2021-03-10
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.